Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $23.7143.

Several brokerages have commented on ZVRA. JMP Securities lowered their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Zacks Research downgraded Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Wall Street Zen lowered Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 20th. Cantor Fitzgerald boosted their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Thursday, July 10th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $9.10 on Wednesday. The stock has a market cap of $510.78 million, a P/E ratio of -43.33 and a beta of 1.56. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The stock’s 50-day moving average price is $10.59 and its two-hundred day moving average price is $8.88. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

Insiders Place Their Bets

In related news, Director John B. Bode purchased 5,000 shares of Zevra Therapeutics stock in a transaction dated Tuesday, August 19th. The stock was bought at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $412,200. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently added to or reduced their stakes in ZVRA. Ameritas Investment Partners Inc. lifted its holdings in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after purchasing an additional 1,280 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Zevra Therapeutics in the 4th quarter valued at approximately $53,000. GAMMA Investing LLC raised its position in Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after buying an additional 8,020 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares in the last quarter. Finally, Creative Planning acquired a new position in Zevra Therapeutics during the 2nd quarter worth approximately $92,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.